Study of Sargramostim in Patients With COVID-19

Inclusion Criteria: * Patients aged ≥ 18 years * Patients (or legally authorized decision maker) must provide informed consent * Test positive for SARS-CoV-2 virus by PCR * Admitted to hospital * Presence of acute hypoxemia defined as (either or both) * saturation below 93% on ≥ 2 L/min oxygen supplementation * PaO2/FiO2 below 350 Exclusion Criteria: * Patients requiring invasive (mechanical ventilation) or non-invasive (CPAP, BiPAP for hypoxemia) ventilation or ECMO (Note: oxygen supplementation using high flow oxygen systems or low flow oxygen systems would not exclude patients from this study) * Intractable metabolic acidosis * Cardiogenic pulmonary edema * Hypotension requiring use of vasopressors * Hyperferritinemia (serum ferritin ≥2,000 mcg/L) * White blood cell count \> 50,000/mm3 * Participation in another interventional clinical trial for COVID-19 therapy * Highly immunosuppressive therapy or anti-cancer combination chemotherapy within 24 hours prior to first dose of sargramostim * Known or suspected intolerance or hypersensitivity to sargramostim, or any component of the product * Previous experience of severe and unexplained side effects during aerosol delivery of any kind of medical product * Presence of any preexisting illness that, in the opinion of the Investigator, would place the patient at an unreasonably increased risk through participation in this study * Pregnant or breastfeeding females * Severe or uncontrolled pulmonary comorbid conditions, inc…